News Sentiment

MLYS sentiment intelligence

Mineralys Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 69 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 27.09 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.5% over one week, +10.0% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction -4.5% Price reacting lower
Trend fit Trend inactive 10.0% over four weeks
Fair value 49.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 47
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
Market source 11
Investing.com 4
Motley Fool 3
Investing.com South Africa 2
Investing.com Canada 2
Quartr 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 50
Earnings 15
Deals and strategy 2
Regulatory and legal 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 69
Stock Titan Direct company coverage

Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise

An affiliate of Mineralys Therapeutics (MLYS) has filed a Form 144 notice for the potential sale of 7,438 shares of common stock. This sale, valued at $199,884.80, is scheduled for July 21, 2026, following the exercise of employee stock options via a broker-assisted cashless exer

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 20:40
Source
Stock Titan
Investing.com South Africa Direct company coverage

Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares By Investing.com

Mineralys Therapeutics CMO David Rodman sold 416 shares for $11,036 while simultaneously acquiring the same number of shares by exercising stock options for $6,423 under a pre-arranged trading plan. Post-transaction, Rodman holds 51,384 shares and 3,334 stock options. The company

Tone
Negative 40/100
Event
Market update
Published
21 Jul 2026 15:40
Source
Investing.com South Africa
Investing.com Canada Direct company coverage

Form 4 Mineralys Therapeutics Inc For: 21 July

This article states that a Form 4 was filed for Mineralys Therapeutics Inc. on July 21st, implying a report of changes in beneficial ownership of the company's securities. The content is primarily a placeholder for this regulatory filing, with minimal actual news text and surroun

Tone
Neutral 50/100
Event
Regulatory and legal
Published
21 Jul 2026 09:40
Source
Investing.com Canada
Investing.com Direct company coverage

Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares

Mineralys Therapeutics' Chief Medical Officer, David Rodman, recently sold 416 shares for $11,036 and simultaneously acquired 416 shares through stock option exercise for $6,423. These transactions were under a Rule 10b5-1 trading plan. The company's stock has seen a 96% return o

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 09:40
Source
Investing.com
Investing.com Canada Direct company coverage

Form 144 Mineralys Therapeutics For: 17 July By Investing.com

This article from Investing.com is a brief notice about a Form 144 filing for Mineralys Therapeutics (MLYS) on July 17. Form 144 is an SEC filing that indicates an intent to sell restricted securities. The article provides minimal detail beyond this announcement.

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 21:11
Source
Investing.com Canada
Stock Titan Direct company coverage

Mineralys Therapeutics (MLYS) insider schedules 416-share sale after option exercise

Mineralys Therapeutics (MLYS) insider David Rodman has scheduled a sale of 416 common shares on July 17, 2026, following the exercise of employee stock options via a cashless exercise through Merrill Lynch. This notice also details several prior share sales by Rodman between Apri

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 20:09
Source
Stock Titan
Quartr Direct company coverage

Mineralys Therapeutics (MLYS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Mineralys Therapeutics (MLYS) provided updates at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. Key announcements included the late 2025 NDA submission for lorundrostat with a PDUFA date of December 6, 2026, and preparations for its launch. The company also

Tone
Positive 71/100
Event
Market update
Published
16 Jul 2026 21:09
Source
Quartr
Quartr Direct company coverage

Mineralys Therapeutics (MLYS) Q3 2025 earnings summary

Mineralys Therapeutics (MLYS) reported its Q3 2025 earnings, highlighting plans for NDA submission of lorundrostat by early 2026 following positive FDA feedback. The company's cash position of $593.6 million is expected to fund operations into 2028, with significant public equity

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 10:40
Source
Quartr
Investing.com Nigeria Direct company coverage

Form 4 Mineralys Therapeutics Inc For: 15 July By Investing.com

This article reports on a Form 4 filing for Mineralys Therapeutics Inc. for July 15. The brief piece includes the company's stock symbol (MLYS) and a minor percentage change. The content primarily lists market data for various indices, commodities, bonds, and shares.

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 02:39
Source
Investing.com Nigeria
GuruFocus Direct company coverage

Insider Sell: CEO Jon Congleton Sells 10,700 Shares of Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton sold 10,700 shares on July 13, 2026, reducing his total holdings to 603,621 shares. This transaction is part of a trend of more insider selling than buying at the company over the past year. Shares were trading at $27.24 at the

Tone
Negative 30/100
Event
Market update
Published
16 Jul 2026 02:39
Source
GuruFocus
Investing.com Direct company coverage

Mineralys Therapeutics CEO Jon Congleton sells $291,441 in stock

Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares of company stock, valued at $291,441, on July 13, 2026, as part of a pre-planned trading arrangement. Following this sale, Congleton still owns 603,621 shares. The company's stock has seen a significant return over the p

Tone
Negative 40/100
Event
Market update
Published
16 Jul 2026 01:39
Source
Investing.com
Investing.com Direct company coverage

Mineralys therapeutics CMO Rodman sells $556,671 in shares

Mineralys Therapeutics' Chief Medical Officer, Rodman David Malcom, sold company shares totaling $556,671 across two transactions in July 2026, executed under a pre-arranged trading plan. Concurrently, he acquired shares worth $102,365 through stock option exercises. The company

Tone
Negative 39/100
Event
Market update
Published
16 Jul 2026 01:39
Source
Investing.com
Stock Titan Direct company coverage

Mineralys Therapeutics (MLYS) CMO sells 20,407 shares and exercises options

Mineralys Therapeutics (MLYS) Chief Medical Officer David Malcom Rodman sold 20,407 common shares and exercised options for 14,058 common shares on July 13 and 15, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these

Tone
Negative 32/100
Event
Market update
Published
16 Jul 2026 00:40
Source
Stock Titan
Stock Titan Direct company coverage

Mineralys Therapeutics (MLYS) CEO logs 10,700-share sale under Rule 10b5-1 plan

Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares of common stock on July 13, 2026, at a weighted-average price of $27.2375 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in January 2025. Following the sale, Congleton dir

Tone
Negative 40/100
Event
Market update
Published
16 Jul 2026 00:39
Source
Stock Titan
Stock Titan Direct company coverage

Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS)

An insider at Mineralys Therapeutics (NASDAQ: MLYS), David Rodman, plans to sell 6,349 shares of common stock through Merrill Lynch on July 15, 2026, with an aggregate market value of approximately $168,954.55. These shares were acquired via an exercise of employee stock options

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:39
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 144 Mineralys Therapeutics For: 13 July By Investing.com

The article announces the filing of Form 144 for Mineralys Therapeutics on July 13. It is a brief report from Investing.com, likely indicating an insider transaction or a notice of proposed sale of securities. The article provides minimal detail beyond the date and company name,

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 02:10
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Mineralys Therapeutics (MLYS) insider plans 10,700-share Rule 144 stock sale

Mineralys Therapeutics (MLYS) insider Jon Congleton plans to sell 10,700 shares of common stock under Rule 144, valued at $291,441.17. The sale, set for July 13, 2026, via Merrill Lynch on Nasdaq, follows the vesting of restricted stock units. Congleton has made previous sales to

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Mineralys Therapeutics (MLYS) insider details stock option exercise and sales

An affiliate of Mineralys Therapeutics, Inc. (MLYS) has a planned sale of common stock via Merrill Lynch on NASDAQ, stemming from an employee stock option exercise on July 13, 2026. Insider David Rodman has made multiple open-market sales of the company's common stock in the past

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of Mineralys Therapeutics, Inc. – NASDAQ:MLYS

This article provides details about Mineralys Therapeutics, Inc. (NASDAQ: MLYS), including its stock information, market status, and links to financial data, news, and community discussions on TradingView. It also lists the various data providers for the information presented.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 08:39
Source
TradingView
Investing.com Direct company coverage

Mineralys Therapeutics CMO Rodman sells $65,781 in stock

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 2,171 shares of the company's stock for $65,781 on July 9, 2026, under a Rule 10b5-1 trading plan. This sale occurred after the stock delivered a 94% return over the past year, though shares are currently tr

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 07:10
Source
Investing.com
Stock Titan Direct company coverage

Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised 2,171 stock options at $16.00 per share and subsequently sold the same number of common shares at $30.30 per share. This transaction was pre-planned under a Rule 10b5-1 trading plan adopted in October 2

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 00:40
Source
Stock Titan
Investing.com South Africa Direct company coverage

Form 4 Mineralys Therapeutics Inc For: 10 July By Investing.com

This article reports on a Form 4 filing for Mineralys Therapeutics Inc. dated July 10, indicating an insider transaction for the company. The brief mention includes the stock symbol MLYS, which saw a -2.00% change.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:40
Source
Investing.com South Africa
Stock Titan Direct company coverage

Mineralys (MLYS) reports 2,171-share exercise; Rodman sales listed

Mineralys Therapeutics, Inc. (MLYS) filed a Form 144 disclosing a broker-assisted cashless exercise of 2,171 shares on July 9, 2026. The filing also details multiple sales by David Rodman between April 9, 2026, and June 17, 2026, with individual transactions ranging from 416 to 1

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:11
Source
Stock Titan
Sahm Direct company coverage

Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?

Mineralys Therapeutics (MLYS) recently experienced removal from Russell indices but simultaneously announced new ENDO 2026 data, a $150 million public offering, and expanded global rights to its lead drug, lorundrostat. These developments, coupled with a $500 million loan facilit

Tone
Positive 63/100
Event
Market update
Published
07 Jul 2026 06:40
Source
Sahm